Abstract 64P
Background
KRAS is a frequent oncogene in human cancer and is an interesting therapeutic target due to its critical function in many malignancies. Although RAS was previously considered undruggable, recent successful identification of covalent inhibitors has shed light on the potential for cancer treatment. In drug research, RAS enzymatic activity is often measured, but methods based on RAS thermal stability (TSA) are also found useful. In these assays, RAS binding ligands stabilizes the structure over the native conformation and shifts its denaturation temperature. Among TSAs, differential scanning fluorimetry (DSF) has gained the most attention due to method’s good throughput. However, DSF lacks the needed sensitivity and results are markedly TSA dye-dependent. In addition, ligand behavior might vary when measured over the physiological temperature. In some cases, binding affinities obtained using isothermal chemical denaturation (ICD) have been found more reliable. Commonly used chemical denaturants like urea and guanidium chloride can be used to provide reliable information on ligand binding in a concentration dependent manner. However, these denaturants often require long incubation time and may affect the affinity of ionic compounds at high concentrations.
Methods
To overcome the difficulties in TSA and ICD techniques, we have developed a modification of the Protein-Probe (PP) technique, to measure isothermal protein stability at mild ICD conditions over time. The principle of this method is based on designed dual-labeled peptide-probe, and time-resolved Förster resonance energy transfer (TR-FRET) monitoring.
Results
As a model KRAS mutation, we studied KRAS(G12C) (50 nM) interaction with the most promising covalent inhibitors. Inhibitor induced stabilization of KRAS(G12C) can be monitored directly from the signals in a dose dependent manner in less than 60 min. The same effect was not seen with G12V.
Conclusions
ICD combined with the novel FRET-probe is a prominent option for TSAs, as no special equipment are needed. Isothermal concept can also potentially provide more understanding of how these proteins behave in vivo.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Academy of Finland and Otto A. Malm Foundation.
Disclosure
H. Härmä, K. Kopra: Financial Interests, Personal, Ownership Interest: QRET Technologies Oy. All other authors have declared no conflicts of interest.
Resources from the same session
38P - Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
Presenter: Yujun Hu
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
Presenter: Tamanna Lakhanpal
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
Presenter: Beatriz Alonso de Castro
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
Presenter: Nano Pachuashvili
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
Presenter: Lauren Wood
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Presenter: James Levin
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
Presenter: Xiao Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
Presenter: Merve Özkan
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
Presenter: Carolina Trabulo
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract